# Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

> **NCT00861744** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1259 (actual)

## Conditions studied

- Rubella
- Mumps
- Measles
- Measles-Mumps-Rubella Vaccine

## Interventions

- **BIOLOGICAL:** GSK Biological's investigational vaccine 209762
- **BIOLOGICAL:** M-M-R® II (Merck and Co)
- **BIOLOGICAL:** Varivax®
- **BIOLOGICAL:** Havrix®
- **BIOLOGICAL:** Prevnar®

## Key facts

- **NCT ID:** NCT00861744
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06-03
- **Primary completion:** 2010-07-21
- **Final completion:** 2012-06-18
- **Target enrollment:** 1259 (ACTUAL)
- **Last updated:** 2020-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00861744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00861744, "Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT00861744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*